Good morning, and welcome to the Scandion Oncology Investor Call. Throughout this call, all participants will be on listen-only mode. Afterwards, there will be a Q&A. If you have a question, please press zero one on your telephone keypad. Today, I'm pleased to present CEO Bo Rode Hansen and CFO Johnny Stilou. Please begin. Thank you. Good morning, everyone, and welcome to this teleconference, where we will speak about the upcoming rights issue which was announced on June 1st. As you just heard, if anybody doesn't know, my name is Bo Rode Hansen, and I'm the CEO and President of Scandion Oncology. With me today is our CFO, Johnny Stilou, who will talk you through the technical aspects and terms and the timelines of the rights issue. Before that, I will tell you about the issue in the context of our strategy and tactical plans, including how we intend to invest the upcoming proceeds. Following our presentation, we are very happy to take your questions. Again, welcome, and thank you for your interest in Scandion. Next slide, please. As always, before we begin, let me just remind you that we will be making forward-looking statements during this call and that those are by nature subject to significant risks and uncertainties as described in this disclaimer. Moving on to slide 3 for the agenda for this call. During the call today, I will update you on the rights issue and on how the rights issue will help fund the execution of our strategy, primarily the development of our lead asset, SCO-101, and how we plan to approximately double the commercial potential in colorectal cancer. Johnny will provide details on the technical and practical aspects of the rights issue before we will end with a reminder of our core strengths as a company. The next slide, please. At Scandion, we discover and develop first-in-class medicines, and they are aimed at treating cancer which is resistant to current treatment options. In that sense, we are among the world's leaders in reverting cancer's resistance against treatment and thus making the treatment work better and longer, and thereby potentially prolonging and improving the lives of patients who would otherwise have a high risk of losing their life due to their cancer. This will, of course, also improve the lives for not only the patients but also their relatives, and as such, it's a big mission. Globally, close to 10 million patients die every year from treatment-resistant cancers. To us, this is simply unacceptable, and help bringing this number down is really what motivates us going to work every day. We have both the expertise and the molecules to help solve this massive problem in cancer treatment. All of our plans aim to revert cancer drug resistance and make existing therapies work better and longer. Again, this would benefit patients, caregivers, society, and also our owners. We are hopeful that we can make a big advancement in cancer treatment and bring down the numbers of people who lose their lives to this horrible disease. Our medicines are relevant for several cancers. This gives us the potential to provide treatment to millions of people who today don't have effective treatment options. That makes both our medical and commercial potential significant. In 2022 will be for us a landmark year at Scandion as we hope and expect to take significant steps towards realizing the potential I just spoke to. The rights issue is a very important component in this regard, as it will help us to fund both the next part of developments of our lead asset, SCO-101, but also our pipeline and the company, overall. I will come back to that shortly. Firstly, let me explain the rights issue in relation to our long-term strategy and also the timing of it. Please turn to Slide five. As a biotech company, we invest in developing new and better medicines. As we do not have a product on the market, we burn cash as we invest, such as the common business model in biotech. This implies that we need to secure funding as we progress the development of our assets and the company. Through development, the value of our asset should grow over time, exceeding the value of the money that was invested in the development. This is a business case. We have clear priorities when thinking about how to fund the company. Obviously, the cost of capital is essential, and so is the timing of each capital injection. Ideally, we secure financing well in advance of our current cash running out. Getting too close to this point of running out of cash will make it harder and more expensive to secure additional funds. Before this rights issue, our cash position would take us into 2023, as stated on numerous occasions. That meant that we would need to find additional capital sometime during the year that we end in 2022, as also stated. That is what we are executing on with the rights issue, and we are doing that exactly as planned. Doing this now means we extend our cash position to take the company into 2024. That we can plan ahead and therefore seamlessly continue our development activities as data will allow, without having to wait to secure the money after having seen the data. This is very important in our long-term value creation. We have many reasons to be excited right now to announce this capital raise. Another one is actually the confidence it shows from investors that we have at least 80% of the proceeds guaranteed. As you may know, the financial markets are changed and very difficult now, and biotech share prices have in general declined severely in the recent months. For us to be able to carry through this rights issue in this environment is a testament to the belief in the company from the financial markets. Next slide, please. Looking specifically at our development assets, we see a massive potential in SCO-101 in multiple cancers and in combination with multiple therapies as reflected on the slides you see. Development is most advanced within metastatic colorectal cancer, and we have now identified opportunities to approximately double the commercial potential in this indication. We expect to invest most of the proceeds from the rights issue in these efforts, expanding the clinical development in this indication to also explore the RAS-mutated patients as we had talked to before. The CORIST trial is spearheading clinical development within cancer drug resistance globally. We expect data in the second or most likely the third quarter of 2022. This could provide the clinical proof of concept which would be the first in the world for a molecule working in the way that SCO-101 is, and no drug on the market today can do what we believe we can do with SCO-101. We are already planning the first steps of pivotal development of SCO-101 in colorectal cancer. By securing additional funding through this rights issue now, we will have the financial capacity to seamlessly continue our development activities right after the data readout. This is much better than having to await data before seeking additional funding as that comes, or that could potentially delay the development for weeks or months and losing the momentum in the clinical development. By raising capital now, we can optimize our development plans and make sure that we can execute on them as soon as data allows. This will also allow us to utilize the good momentum built from the internationalization of the CORIST trial earlier this year. Let me stress that the rights issue changes nothing in our overall strategy. That means we can continue to explore opportunities to potentially conduct pivotal development in one or more partnerships as well. There is also no changes to the PANTAX trial, which remain ongoing as expected, for readout in Q2 or most likely Q3. Confirming the broad potential we see for SCO-101 are a number of highly promising findings that we made when combining the compound with immune therapies in preclinical studies. From what we know today, SCO-101 might enhance immunotherapies in multiple cancers, which would be, of course, another significant opportunity that we have to look into at Scandion. We plan to use parts of the proceeds from the rights issue to conduct preclinical development and explore the position to use SCO-101 and other candidates for that matter in combination with, for instance, immunotherapy, but also other chemotherapies. With that, I will now hand over to Johnny for an overview of the rights issues, the terms and timelines. Johnny, please go ahead. Thank you, Bo, and please turn to slide 7. This slide describes our intended use of proceeds from the rights issue. As just explained by Bo, we plan to invest the majority of the proceeds in expanding the clinical development of SCO-101 and additionally in preclinical development within immunotherapy area. Finally, a smaller portion of the proceeds is planned to be invested in the overall development of Scandion as a listed clinical-stage biotech company and attractive investment case also for institutional investors. We have already commenced this journey. As an example, our financial reporting is now done by IFRS, and we see an uplisting to a main market as a natural step in the future. Next slide, please. These are the terms of the rights issue. Should all shares be subscribed for, the full proceeds will be approximately SEK 93.7 million before deduction of transaction costs of approximately SEK 17 million, equaling net proceeds of around SEK 76.7 million. As Bo alluded to, the rights issue will enhance our cash position and extend our cash runway throughout 2023 and into 2024. For one existing share, shareholders will receive one subscription right. Three subscription rights entitled to subscribe for one new share in the company. The subscription price will be 8.75 SEK per share. Subscription and guarantee commitments have been received from current and new investors amounting to approximately SEK 75 million corresponding to approximately 80% of the issue. Please turn to next slide. The rights issue will be carried through in accordance with the timetable as shown here. On June 15, we expect to publish the prospectus, and on the day after, on June 16, the trading period will start and commence until July 1. On July 5, the announcement of the outcome of the rights issue will be published. As is common for transactions of this nature, Scandion's board members and executive management who own shares in Scandion have undertaken a lock-up not to transfer or otherwise sell the shares for a period of 180 days after the end of the subscription period. With this, I hand the word back to Bo for his closing remarks. Yeah. Thank you very much, Johnny, and please turn to slide 10. Let me sum up our presentation here by underlying the fact that we are pleased to be able to carry through this rights issue, strengthening our financial position to support the execution of development plans completely in accordance with our strategy. We believe this is the optimal time allowing for long-term planning and seamlessly continuation of the development following data readout. 2022 will be a landmark year for us during which we will have at least two potential huge value inflection points with the readouts from the CORIST and the PANTAX trials. We will continue to leverage our strength as first movers in the cancer drug resistance with both a significant medical and commercial potential. We have de-risked SCO-101, and our pipeline provides several opportunities to expand into different therapy combinations and also cancers. We have built a strong organization of seasoned, and also a seasoned leadership team, and we are ready to further develop the company based on what we hope is a positive readout from our clinical trials. With that, I conclude our presentation, and really thank you for your attention. We are ready now to take your questions. Back to the operator. Thank you, Bo. If you do wish to ask a question, please press zero one on your telephone keypad. There will be a brief pause while questions are being registered. Maybe you can take some written questions while we're waiting for the telephone questions. Okay. Do we have some written questions? Yes, we have some written questions. Let's see here. We have a question here that says, what do you mean by doubling the potential? The strategy for this study was first to include RAS mutated, and now you change to not include them, and they are back again. No. What we mean is that when the CORIST, which was a composite phase II trial, continuing from part one into part two, the company focused on the patients having an identified RAS wild type tumor profile. This was due to the interim readout we reported in June last year, and in order to focus on getting the maximum likelihood of a clear response with the number of patients in part two. Now what we said also at our capital markets day last year and during the past 12 months is that we haven't forgotten about the patients with the RAS mutated cancers. Now we are going in and focusing on them in order to provide the largest potential for therapeutic reach in metastatic colorectal cancer and thereby approximately doubling the number of patients that could benefit from this. This is requiring some specific focus. At the end of the day, we would aim at treating as many patients as possible and thereby enlarging the potential. Thank you. We have a question from the telephone conference, and it's from Joey Schreids from Edison Investment Research. Joey, please go ahead. Your line is open. Hi, Bo. Hi, Johnny. It's Harry here from Edison. Congratulations on the financing, by the way. It's been really good to see. On the mutant RAS again, I was just wondering how are you guys looking at pursuing this? I mean, given you had some data for the biomarker for CORIST part two, sort of what are these studies gonna look like, if you can tell us? And what's the rationale behind pursuing mutant RAS? Yes, and thanks for the question. As we said, in my previous reply, we focused on the part two of CORIST on the patients with the wild-type tumors and thereby excluding the potential for patients with RAS mutated. This required that we go back and include these patients looking at what would be, you can say, the optimal conditions for getting these patients included into the group before defining the final design for a randomized controlled study. This is in the aim of actually both reaching the broadest possible metastatic colorectal cancer patient population and as a potential for moving up the line subsequently. This will look the same as CORIST part two. We're just beginning to enroll mutant RAS patients. No, not exactly. I mean, because what we saw from the earlier studies was that the results led us to focus on the wild type. This requires that we look at the mutated patients again, and optimize exactly how this looks for setting up the final design. This is, you can say it might, but this is what the study is set out to actually also conclude on so that we get the maximum potential for treating most patients at the end of the day. Okay. Thank you. Finally, can you give us an idea of sort of how much of the funds, maybe assuming you get the full amount you're after, will you be earmarking for the RAS development, sorry, the CORIST development in mutant RAS and sort of preclinical work and immuno-oncology work? Yeah. Well, I mean, in terms of distribution of the use of proceeds, I mean, 80% will be aimed at the development of SCO-101 according to what we just talked about. Fifteen percent of the use of proceeds will be focused on our preclinical pipeline development for you can say sustained value creation in connection with what we are doing in the clinic. Brilliant. Thank you very much, Bo, and thanks, Johnny, and congratulations again on the fundraising. Thank you. There are no more questions at this time at the telco, so if you have any more written questions, I'll hand it right back to you. Yes. We have some additional questions. We have a question here. Bo, you are talking of providing value over time. As an investor since IPO, and been taking place and all the rights issue, there is no value increase over the time the company has been listed. When is the company planning to give value increase to its long-term investors? You know, our focus is on creating value every day. I think the company has created significant fundamental value over the course of time since the IPO. At the end of the day, we are developing a product which is by nature requiring long development timelines and requiring substantial financial investments in order to make it to the finish line. I think in terms of value creation, making it to the finish line with a drug that is first in class and potentially transforming a big problem in medical oncology, I foresee a very strong value creation from that. That's also historically warranted. Okay. Thank you. Another question here. After all the filings and new warrants, for some reason, though, you still have your old warrants with the dilution protection. What will be their exercise price of the adjustment for this emission? I can take that question. As you may recall, when we got the authorization to issue the new ones under the new program, one of the terms were that the old or existing warrant programs will be forbidden. Meaning that when a warrant recipient receives the new warrants, they will have to decline on their current warrant programs. That also goes for Bo Rode Hansen. Following the execution of the current authorization, the old warrant programs will all disappear. Thank you. I have another question here. How will phase III be financed? Do you already have a partner for this? In terms of phase III, again, developing a drug to market requires the time and the capital strength to do that. The actual financial or the capital to do that can come from different sources. One thing is through what we are doing now, this type of rights issues. Another way is to engage into a partnership by sharing risks and upside and thereby getting some co-financing or financing for that. We are operating as most biotechs also according to the same model. We are pursuing the possibilities in the interest of making the best value creation and also eventually return to our investors. Thank you. We have a question in relation. You mentioned that we could expect partnership within 12-18 months in 2020. Can you tell us more about that? Expectations for things in the future can be stated in many ways. I mean, the premise for the question is somewhat imprecise. What I stated in the past is that we are in continuous dialogue with the community just as any biotech would be in order to develop our products. We can see a path where partnerships can bring both the strategic and financial resources to develop this all the way to the finish line, and it needs to be done at the right time point for reflecting value. The data needs to be of impressive quality that the right partner engages on this. All this is according to our strategy and what we are working on. In terms of setting a finite date on a partnership, this is not doable in this context. Well, thank you both. With that, we have no more questions. There are no more questions at the telephone conference either. I just hand the word back to you, Bo Rode and Johnny, for some closing remarks. Okay. With that, we thank you very much again for your interest and participating in this call. We look forward to continuing the journey with you also through this rights issue. With that, we conclude today's presentation. Thank you.